Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis RegistryP J Mease, J B Palmer, P Hur, et al.Journal of the American Academy of Dermatology|September 27, 2000
Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled studyA B Gottlieb, M Lebwohl, S Shirin, et al.Journal of the American Academy of Dermatology|March 1, 1991
A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasisE A Olsen, D L Cram, C N Ellis, et al.The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 7, 2018
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foamA Jalili, M Lebwohl, L Stein Gold, et al.Journal of the American Academy of Dermatology|February 25, 2000
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasisA Gottlieb, J G Krueger, R Bright, et al.Pageof 13